Recent advances in the treatment of cardiovascular diseases with roxadustat
10.20039/j.cnki.1007-3949.2024.05.013
- VernacularTitle:罗沙司他治疗心血管疾病的最新进展
- Author:
Wei BAO
1
;
Yunbo LÜ
;
Huibo WANG
;
Ting HU
Author Information
1. 三峡大学人民医院心血管内科,湖北省宜昌市 443000
- Keywords:
roxadustat;
cardiovascular diseases;
hypoxia inducible factor;
prolyl hydroxylase
- From:
Chinese Journal of Arteriosclerosis
2024;32(5):456-460
- CountryChina
- Language:Chinese
-
Abstract:
Cardiovascular diseases are still one of the diseases that lead to high mortality.Currently,drugs for preventing and treating cardiovascular diseases can significantly improve symptoms,but there are still shortcomings in re-ducing mortality rates.Therefore,new drugs that can improve symptoms and reduce mortality are needed.As a kind of hydroxylase inhibitor,roxadustat can effectively improve the symptoms of hypoxia by regulating the expression of hypoxia in-ducible factor(HIF).HIF is involved in almost all developmental,pathological or physiological processes in the body,including erythropoietin production,iron uptake,and metablism,cellular differentiation,energy metablism,inflammation and immune regulation.At present,the drug has a good prospect in the treatment of renal anemia,but it is rarely used in cardiovascular diseases.In this paper,the effects of roxadustat on cardiovascular diseases were systematically and com-prehensively discussed,and some help was provided for the treatment of cardiovascular diseases.
